Ovid Therapeutics (OVID) - 2025 Q4 - Earnings Call Presentation

Business and pipeline update March 18, 2026 © Copyright 2026 Ovid Therapeutics Forward-looking statements This presentation includes certain disclosures by Ovid that contain "forward-looking statements" including, without limitation statements regarding: the reproducibility and durability of any favorable results initially seen to date in clinical trials; the potential therapeutic opportunity of OV329, OV4071 and other compounds from Ovid's library of direct activators of KCC2; the expected timing of initia ...